Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a multi-center, prospective, single-arm, non-randomized, interventional phase II study of CML patients in first or second chronic phase (i.e. after allogeneic stem cell transplantation) and proven BCR::ABL1 T315I mutation. All patients will be treated with asciminib 200 mg BID. 50 patients will be enrolled from approximately 20 study sites in Germany.
Epistemonikos ID: b780fb578452bd50bdb14dee4a65f19583f56948
First added on: Aug 27, 2026